Early Endothelial Progenitor Cells (eEPCs) in systemic sclerosis (SSc) - Dynamics of cellular regeneration and mesenchymal transdifferentiation

BMC Musculoskeletal Disorders

Volumn 17, Issue 1, 2016, Pages

  Patschan, S ^a   Tampe, D ^a   Muller C ^a   Seitz, C ^a   Herink, C ^a   Muller G A ^a   Zeisberg, E ^a   Zeisberg, M ^a   Henze, E ^a   Patschan, D ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; AZATHIOPRINE; BOSENTAN; CD31 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; INTERFERON; PREDNISOLONE; TRANSFORMING GROWTH FACTOR BETA; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD SAMPLING; CELL ACTIVITY; CELL COUNT; CELL MIGRATION; CELL MOTILITY; CELL REGENERATION; CELL TRANSDIFFERENTIATION; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MALE; MESENCHYMAL STEM CELL; MONONUCLEAR CELL; PROSPECTIVE STUDY; STIMULATION; SYSTEMIC SCLEROSIS; BLOOD; CASE CONTROL STUDY; CELL MOTION; DIFFUSE SCLERODERMA; LIMITED SCLERODERMA; MIDDLE AGED; PHYSIOLOGY; REGENERATION;

BIOMARKERS; CASE-CONTROL STUDIES; CELL MOVEMENT; CELL TRANSDIFFERENTIATION; ENDOTHELIAL PROGENITOR CELLS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGENERATION; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED;

EID: 84987959461     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/s12891-016-1197-2     Document Type: Article

References (41)

1. Goldblatt F, O'Neill SG. Clinical aspects of autoimmune rheumatic diseases. Lancet Lond Engl. 2013;382:797-808.
2. Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum. 2013;65:1953-62.
3. Mowat A. Connective tissue diseases. Clin Haematol. 1972;1:573-94.
4. Manno R, Boin F. Immunotherapy of systemic sclerosis. Immunotherapy. 2010;2:863-78.
5. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964-7.
6. Case J, Mead LE, Bessler WK, Prater D, White HA, Saadatzadeh MR, et al. Human CD34 + AC133 + VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol. 2007;35:1109-18.
7. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2007;109:1801-9.
8. Basile DP, Yoder MC. Renal endothelial dysfunction in acute kidney ischemia reperfusion injury. Cardiovasc Hematol Disord Drug Targets. 2014;14:3-14.
9. Chen J, Chen J, Chen S, Zhang C, Zhang L, Xiao X, et al. Transfusion of CXCR4-primed endothelial progenitor cells reduces cerebral ischemic damage and promotes repair in db/db diabetic mice. PLoS One. 2012;7, e50105.
10. Martí-Fàbregas J, Crespo J, Delgado-Mederos R, Martínez-Ramírez S, Peña E, Marín R, et al. Endothelial progenitor cells in acute ischemic stroke. Brain Behav. 2013;3:649-55.
11. Patschan S, Patschan D, Henze E, Blaschke S, Wessels JT, Müller G-A. Impairment and differential expression of PR3 and MPO on peripheral myelomonocytic cells with endothelial properties in granulomatosis with polyangiitis. Int J Nephrol. 2012;2012:715049-12.
12. Zhao YH, Yuan B, Chen J, Feng DH, Zhao B, Qin C, et al. Endothelial progenitor cells: therapeutic perspective for ischemic stroke. CNS Neurosci Ther. 2013;19:67-75.
13. Patschan SA, Patschan D, Temme J, Korsten P, Wessels JT, Koziolek M, et al. Endothelial progenitor cells (EPC) in sepsis with acute renal dysfunction (ARD). Crit Care Lond Engl. 2011;15:R94.
14. Allanore Y, Batteux F, Avouac J, Assous N, Weill B, Kahan A. Levels of circulating endothelial progenitor cells in systemic sclerosis. Clin Exp Rheumatol. 2007;25:60-6.
15. Del Papa N, Quirici N, Soligo D, Scavullo C, Cortiana M, Borsotti C, et al. Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum. 2006;54:2605-15.
16. Distler JHW, Allanore Y, Avouac J, Giacomelli R, Guiducci S, Moritz F, et al. EULAR scleroderma trials and research group statement and recommendations on endothelial precursor cells. Ann Rheum Dis. 2009;68:163-8.
17. Fadini GP, Losordo D, Dimmeler S. Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res. 2012;110:624-37.
18. Patschan D, Patschan S, Henze E, Wessels JT, Koziolek M, Müller GA. LDL lipid apheresis rapidly increases peripheral endothelial progenitor cell competence. J Clin Apheresis. 2009;24:180-5.
19. Patschan S, Patschan D, Potulski M, Henze E, Scholze J, Müller G-A. Endothelial progenitor cells in systemic lupus erythematosus. J Nephrol. 2013;26:1065-72.
20. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65:2737-47.
21. LeRoy EC, Medsger TA. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28:1573-6.
22. Patschan S, Nemirovsky K, Henze E, Scholze J, Müller GA, Patschan D. Tocilizumab increases EPC regeneration in rheumatoid arthritis. Scand J Rheumatol. 2014;43:528-30.
23. Xavier S, Vasko R, Matsumoto K, Zullo JA, Chen R, Maizel J, et al. Curtailing endothelial TGF-β signaling is sufficient to reduce endothelial-mesenchymal transition and fibrosis in CKD. J Am Soc Nephrol JASN. 2015;26:817-29.
24. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med. 2003;9:964-8.
25. Jimenez SA. Role of endothelial to mesenchymal transition in the pathogenesis of the vascular alterations in systemic sclerosis. ISRN Rheumatol. 2013;2013:835948.
26. Abraham D, Distler O. How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther. 2007;9 Suppl 2:S2.
27. Kahaleh B. Vascular disease in scleroderma: mechanisms of vascular injury. Rheum Dis Clin North Am. 2008;34:57-71. vi.
28. Müller-Ladner U, Distler O, Ibba-Manneschi L, Neumann E, Gay S. Mechanisms of vascular damage in systemic sclerosis. Autoimmunity. 2009;42:587-95.
29. Neidhart M, Kuchen S, Distler O, Brühlmann P, Michel BA, Gay RE, et al. Increased serum levels of antibodies against human cytomegalovirus and prevalence of autoantibodies in systemic sclerosis. Arthritis Rheum. 1999;42:389-92.
30. Pandey JP, LeRoy EC. Human cytomegalovirus and the vasculopathies of autoimmune diseases (especially scleroderma), allograft rejection, and coronary restenosis. Arthritis Rheum. 1998;41:10-5.
31. Renaudineau Y, Grunebaum E, Krause I, Praprotnik S, Revelen R, Youinou P, et al. Anti-endothelial cell antibodies (AECA) in systemic sclerosis - increased sensitivity using different endothelial cell substrates and association with other autoantibodies. Autoimmunity. 2001;33:171-9.
32. Trojanowska M. Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat Rev Rheumatol. 2010;6:453-60.
33. ÓRiordan E, Mendelev N, Patschan S, Patschan D, Eskander J, Cohen-Gould L, et al. Chronic NOS inhibition actuates endothelial-mesenchymal transformation. Am J Physiol Heart Circ Physiol. 2007;292:H285-94.
34. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007;13:952-61.
35. Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol JASN. 2008;19:2282-7.
36. Guiducci S, Manetti M, Romano E, Mazzanti B, Ceccarelli C, Dal Pozzo S, et al. Bone marrow-derived mesenchymal stem cells from early diffuse systemic sclerosis exhibit a paracrine machinery and stimulate angiogenesis in vitro. Ann Rheum Dis. 2011;70:2011-21.
37. Stoelting S, Trefzer T, Kisro J, Steinke A, Wagner T, Peters SO. Low-dose oral metronomic chemotherapy prevents mobilization of endothelial progenitor cells into the blood of cancer patients. Vivo Athens Greece. 2008;22:831-6.
38. Cutolo M, Ruaro B, Pizzorni C, Ravera F, Smith V, Zampogna G, et al. Longterm treatment with endothelin receptor antagonist bosentan and iloprost improves fingertip blood perfusion in systemic sclerosis. J Rheumatol. 2014;41:881-6.
39. Parisi S, Bruzzone M, Centanaro Di Vittorio C, Laganà A, Peroni CL, Fusaro E. Efficacy of bosentan in the treatment of Raynaud's phenomenon in patients with systemic sclerosis never treated with prostanoids. Reumatismo. 2013;65:286-91.
40. Kill A, Tabeling C, Undeutsch R, Kühl AA, Günther J, Radic M, et al. Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther. 2014;16:R29.
41. Patschan D, Schwarze K, Henze E, Patschan S, Müller GA. Am J Physiol Renal Physiol. 2016 Jan 20:ajprenal.00306.2015. doi: 10.1152/ajprenal.00306.2015. [Epub ahead of print].